Affinity Asset Advisors LLC acquired a new stake in shares of Genelux Co. (NASDAQ:GNLX – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 100,000 shares of the company’s stock, valued at approximately $195,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of GNLX. Woodward Diversified Capital LLC boosted its position in Genelux by 2,326.2% during the 4th quarter. Woodward Diversified Capital LLC now owns 1,082,270 shares of the company’s stock worth $15,163,000 after buying an additional 1,037,663 shares during the period. Highbridge Capital Management LLC acquired a new position in shares of Genelux during the second quarter worth $1,231,000. Miracle Mile Advisors LLC bought a new stake in shares of Genelux in the 2nd quarter valued at about $58,000. Cubist Systematic Strategies LLC bought a new stake in Genelux in the second quarter valued at approximately $56,000. Finally, Clarity Capital Partners LLC acquired a new stake in Genelux during the 4th quarter valued at approximately $364,000. Institutional investors own 37.33% of the company’s stock.
Insider Transactions at Genelux
In other Genelux news, major shareholder Aladar Szalay sold 33,080 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $2.57, for a total transaction of $85,015.60. Following the completion of the sale, the insider now directly owns 599,821 shares of the company’s stock, valued at approximately $1,541,539.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 331,062 shares of company stock valued at $736,831 over the last three months. Corporate insiders own 9.30% of the company’s stock.
Analyst Ratings Changes
Check Out Our Latest Report on GNLX
Genelux Price Performance
GNLX stock opened at $2.18 on Wednesday. The company’s 50-day moving average is $2.20 and its 200-day moving average is $3.16. Genelux Co. has a 1 year low of $1.60 and a 1 year high of $28.36.
Genelux (NASDAQ:GNLX – Get Free Report) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, equities analysts predict that Genelux Co. will post -0.9 EPS for the current fiscal year.
Genelux Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.
See Also
- Five stocks we like better than Genelux
- What is a Death Cross in Stocks?
- Is Rivian Stock a Bargain Buy With 60% Upside Potential?
- Dividend Capture Strategy: What You Need to Know
- 4 Catalysts Poised to Push Caterpillar Stock to Record Highs
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Why Small-Cap Stocks Could Be Ready to Outperform After Rate Cuts
Want to see what other hedge funds are holding GNLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genelux Co. (NASDAQ:GNLX – Free Report).
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.